Back to all Current clinical trials
Back to all Current clinical trials
Teton 2 - New IPF Treatment
Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, efficacy and safety study of subjects with IPF treated with inhaled treprostinil over a 52-week period.
- Category
-
Trial status
Active, not recruiting
-
Trial phase
Phase 3 Drug TrialLate stage studies conducted to confirm efficacy and safety of investigational therapies in large patient populations prior to introduction to clinical practice.
- Registry listing
-
ERM Project ID
87752
Trial contact details
-
Contact person
RIO Clinical Trials Unit
-
Phone
07 3163 1369
What you need to know
Who can take part?
- Eligible subjects must be ≥40 years of age.
- Have a confirmed diagnosis of IPF through HRCT or a surgical lung biopsy.
- FVC ≥45% predicted.
- Subjects on Pirfenidone or Nintedanib must be on a stable and optimized dose for ≥30 days prior to Baseline.
What is involved for you?
The study will run for about 58 weeks and will entail at least 8 visits to the clinical trials unit.
Patients will be required to complete the below;
- Informed Consent
- Eligibility Check
- Medical History, History of IPF and Demographics
- Physical Examination
- Vital Signs
- Urine Pregnancy Test
- ECG or EKG
- Blood Tests
- Study Specific Questionnaires
- Lung Function Tests; Spirometry & DLCO Testing
- Health and Medication Chec
- Participant Device Training
- Complete a Study Drug Diary
- Study Drug Administration
- HRCT
- Weekly Telephone/ Email Contact
Trial dates
September 2022 - November 2024
